Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2) - Forschungsportal der Justus-Liebig-Universität Gießen:

Journalartikel

Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)

Autorenliste: Simonneau, Gerald; D'Armini, Andrea M.; Ghofrani, Hossein-Ardeschir; Grimminger, Friedrich; Hoeper, Marius M.; Jansa, Pavel; Kim, Nick H.; Wang, Chen; Wilkins, Martin R.; Fritsch, Arno; Davie, Neil; Colorado, Pablo; Mayer, Eckhard

Jahr der Veröffentlichung: 2015

Seiten: 1293-1302

Zeitschrift: European Respiratory Journal

Bandnummer: 45

Heftnummer: 5

ISSN: 0903-1936

eISSN: 1399-3003

Open Access Status: Bronze

DOI Link: https://doi.org/10.1183/09031936.00087114

Verlag: European Respiratory Society

Abstract:

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of inoperable and persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH). In the 16-week CHEST-1 study, riociguat showed a favourable benefit-risk profile and improved several clinically relevant end-points in patients with CTEPH. The CHEST-2 open-label extension evaluated the long-term safety and efficacy of riociguat.

Eligible patients from CHEST-1 received riociguat individually adjusted up to a maximum dose of 2.5 mg three times daily. The primary objective was the safety and tolerability of riociguat; exploratory efficacy end-points included 6-min walking distance (6MWD) and World Health Organization (WHO) functional class (FC).

Overall, 237 patients entered CHEST-2 and 211 (89%) were ongoing at this interim analysis (March 2013). The safety profile of riociguat in CHEST-2 was similar to CHEST-1, with no new safety signals. Improvements in 6MWD and WHO PC observed in CHEST-1 persisted for up to 1 year in CHEST-2. In the observed population at 1 year, mean so 6MWD had changed by +51 +/- 62 m (n=172) versus CHEST-1 baseline (n=237), and WHO FC had improved/stabilised/worsened in 47/50/3% of patients (n=176) versus CHEST-1 baseline (n=236).

Long-term riociguat had a favourable benefit-risk profile and apparently showed sustained benefits in exercise and functional capacity for up to 1 year.

Zitierstile

Harvard-Zitierstil: Simonneau, G., D'Armini, A., Ghofrani, H., Grimminger, F., Hoeper, M., Jansa, P., et al. (2015) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2), European Respiratory Journal, 45(5), pp. 1293-1302. https://doi.org/10.1183/09031936.00087114

APA-Zitierstil: Simonneau, G., D'Armini, A., Ghofrani, H., Grimminger, F., Hoeper, M., Jansa, P., Kim, N., Wang, C., Wilkins, M., Fritsch, A., Davie, N., Colorado, P., & Mayer, E. (2015). Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). European Respiratory Journal. 45(5), 1293-1302. https://doi.org/10.1183/09031936.00087114

Zitierstile

Schlagwörter